Navigation Links
FDA Grants Market Clearance to Aerocrine Inc.'s NIOX MINO(R): a New Hand-Held Device to Measure Airway Inflammation in Asthma

NIOX MINO(R) Set to Dramatically Improve Airway Inflammatory Disease

Management through Personalized Inflammation Control

NEW PROVIDENCE, N.J., March 4 /PRNewswire/ -- Aerocrine, Inc. ( today announced that NIOX MINO (, a hand- held point-of-care device for the measurement of airway inflammation, has been 510(k) cleared by the U.S. Food and Drug Administration (FDA). Physicians in the U.S. now have a highly accurate, non-invasive and convenient technology that is appropriate for use in a doctor's office, ultimately helping them improve how they treat asthma patients.

(Photo: )

NIOX MINO provides accurate, reproducible and immediate measurement of fractional exhaled nitric oxide (FENO), a validated method for assessing asthma-related airway inflammation. NIOX MINO is the first hand-held device to measure airway inflammation -- an underlying cause of inflammatory airway diseases -- helping physicians improve patient outcomes and reduce healthcare expenditures.

"NIOX MINO answers the need for a user friendly, non-invasive, accurate, and cost effective tool that enables any physician to monitor the underlying process of asthma-airway inflammation," said Peter B. Boggs, M.D., Clinical Professor of Pediatrics and Medicine, LSU School of Medicine, Shreveport." What is important about this is that the control of airway inflammation is the key to the successful management of asthma, and this tool makes this possible."

Millions of people living with asthma, including many children, are not receiving optimal treatment. All patients are different, requiring different treatments and dosages. Therefore, airway inflammatory disease management and control can be significantly improved through 'personalized' monitoring of the airway inflammation rather than just symptoms.

Among the benefits of NIOX MINO, physicians will have insights into treatment efficacy and can better predict a patients' response to therapy and the risk of an asthma relapse. Moreover, physicians will be able to identify patient non-compliance with medications, and can adjust the dose of medication based on individual patients' needs. NIOX MINO is reimbursable in the U.S. through CPT code 95012. The CPT code only applies to FDA-cleared devices (currently NIOX(R), NIOX(R) Flex and NIOX MINO).

"Historically, monitoring inflammatory airway diseases such as asthma focused primarily on measuring symptoms and lung function," said Trevor Bourke, Aerocrine, Inc." The availability of NIOX MINO in the United States represents a major advance in asthma management, because for the first time, doctors can measure the underlying inflammation that causes asthma within a few minutes directly in their offices."

NIOX MINO offers real-time delivery of accurate FENO measurement results within minutes. The device has been used extensively in Europe, where more than one million FENO measurements have impacted the lives of people living with asthma. Its innovative design has won numerous accolades, including a 2005 Medical Design Excellence Award -- the premier awards program in the medical technology community -- in the category of In Vitro Diagnostics.

FENO measurements by NIOX MINO compare favorably to other asthma monitoring methods in terms of providing accurate and reliable results. FENO measurement is an earlier metric than spirometry -- a test of the lungs' breathing capacity -- to inflammation changes following allergen exposure, making it a more sensitive marker of the disease.

"NIOX MINO measures something we can't feel until it is raging out of control -- airway inflammation," said Nancy Sander, president and founder of Allergy & Asthma Network Mothers of Asthmatics (AANMA). With this simple test, patients and physicians can take a more strategic approach to asthma care with the goal of using less medication to get maximum results."

AANMA is a non-profit health organization that builds understanding, provides practical assistance and helps families breathe easier through education, advocacy and outreach. For more information about AANMA, visit

About Asthma

Asthma is a chronic inflammatory process that leads to airflow limitation and increased sensitivity to asthma triggers. More than 22 million people in the United States are currently affected by asthma. It is one of the most common chronic diseases of childhood, affecting more than six million children.

Asthma has far-reaching social and economic impacts. The annual cost of this disease is estimated to be nearly $18 billion through direct costs of $10 billion, such as hospitalizations, medications and other healthcare costs; and indirect costs of $8 billion, which include lost earnings due to illness, death or absenteeism. In 2002 there were more than 4,000 mortalities due to this chronic condition.

About Aerocrine

Aerocrine AB is a medical technology company focused on the improved management and care of patients with inflammatory airway diseases. As the pioneer and leader in the technology to monitor and manage airway inflammation, Aerocrine markets NIOX(R) Flex and NIOX MINO(R). Both products enable fast and reliable management of airway inflammation and may therefore play a critical role in more effective diagnosis, treatment and follow-up of patients with inflammatory airway diseases such as asthma. Aerocrine is based in Sweden with subsidiaries in the US, Germany and the UK. Aerocrine shares were listed on the Stockholm Stock Exchange on 15 June 2007.

Aerocrine may be required to disclose the information provided herein pursuant to the Securities Markets Act. The information was submitted for publication at 7:55 a.m. on March the 4th 2008.

SOURCE Aerocrine, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Mirus Bio Awarded Grants & Contracts of Over $5 Million
2. FDA Grants Orphan Drug Designation to TREANDA, an Investigational Treatment for Chronic Lymphocytic Leukemia
3. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
4. NIH grants $750,000 to develop device to determine temperature of neonates brain
5. Edwards Lifesciences Grants UC Irvine $5 Million to Establish the Edwards Lifesciences Center for Advanced Cardiovascular Technology
6. Radius Grants Major Pharmaceutical Company Exclusive Option to License BA058 for Osteoporosis
7. Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer
8. CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350
9. NASDAQ Panel Grants Merge Technologies Additional Time to Regain Compliance
10. FDA Grants Resverlogix Approval to Commence a Phase 1 Clinical Trial for RVX-208
11. Maryland Stem Cell Commission Issues Nationwide Request for Applications for New Post-Doctoral Fellowship Grants
Post Your Comments:
(Date:11/27/2015)... , November 27, 2015 ... Growing popularity of companion diagnostics is ... cancer biomarkers market with pharmaceutical companies and ... companion diagnostic tests. . ... Complete report on global cancer biomarkers ...
(Date:11/26/2015)... November 26, 2015 --> ... specializing in imaging technologies, announced today that it has received ... of the Horizon 2020 European Union Framework Programme for Research ... clinical trial in breast cancer. , --> ... --> --> The study aims ...
(Date:11/25/2015)... Nov. 25, 2015  PharmAthene, Inc. (NYSE MKT: PIP) ... a stockholder rights plan (Rights Plan) in an effort ... carryforwards (NOLs) under Section 382 of the Internal Revenue ... PharmAthene,s use of its NOLs could be substantially ... defined in Section 382 of the Code. In general, ...
(Date:11/25/2015)... , November 25, 2015 Studies ... and human plaque and pave the way for more effective ... in cats     --> ... commonly diagnosed health problems in cats, yet relatively little was ... Two collaborative studies have been conducted by researchers from the ...
Breaking Biology Technology:
(Date:11/12/2015)...  Arxspan has entered into an agreement with ... use of its ArxLab cloud-based suite of biological ... will support the institute,s efforts to electronically manage ... internally and with external collaborators. The ArxLab suite ... Institute,s electronic laboratory notebook, compound and assay registration, ...
(Date:11/10/2015)... Nov. 10, 2015 About ... that helps to identify and verify the identity ... considered as the secure and accurate method of ... a particular individual because each individual,s signature is ... especially when dynamic signature of an individual is ...
(Date:11/2/2015)... Nov. 2, 2015  SRI International has been awarded ... preclinical development services to the National Cancer Institute (NCI) ... provide scientific expertise, modern testing and support facilities, and ... pharmacology and toxicology studies to evaluate potential cancer prevention ... The PREVENT Cancer Drug Development Program is an NCI-supported ...
Breaking Biology News(10 mins):